Comparison studies of anti-VEGF agents a 'global effort'

Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney
February 2011
Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25
Academic Journal
The article reports on the presentation by doctor Daniel F. Martin on the comparison studies and international effort to understand the differences between the two anti-vascular endothelial growth factor (VEGF) agents, ranibizumab and bevacizumab.


Related Articles

  • Study supports anti-VEGF, laser for patients with diabetic macular edema. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p24 

    The article reports that intravitreal ranibizumab with deferred or prompt focal/grid laser has resulted to superior to optical coherence tomography outcome and superior visual acuity than in focal/grid laser treatment alone in visually impaired patients according to doctor Neil M. Bressler.

  • Anti-VEGF maintains visual acuity gains at 1 year in patients with neovascular AMD. Hasson, Matt; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;3/25/2011, Vol. 29 Issue 6, p31 

    The article reports on the study which found that pegatinib, an induction-maintenance therapy, can improve visual acuity and stabilized center point thickness in patients that have neovascular age-related macular degeneration.

  • HARBOR study shows similar results for four anti-VEGF dosing regimens. Hasson, Matt // Ocular Surgery News;2/25/2013, Vol. 31 Issue 4, p39 

    The article discusses results of HARBOR study which shows that ranibizumab has yielded similar safety and efficacy results for four anti-vascular endothelial growth factor (VEGF) dosing regimens.

  • Anti-VEGF injections may not be preferred for AMD patients with poor baseline visual acuity. Pagnani, Michelle // Ocular Surgery News;3/25/2012, Vol. 30 Issue 6, p10 

    The article reports on a study which found that for those with age-related macular degeneration and poor baseline acuity, consideration of an alternative to anti-vascular epithelial growth factor (VEGF) therapy may be warranted.

  • Novel therapy targets integrin receptors. Karageozian, Vicken // Ophthalmology Times;Oct2015, Vol. 40 Issue 17, p42 

    The article discusses the result of the clinical trial of ALG-1001 from Allegro Ophthalmics for the treatment of vitreoretinal disease. Topics covered include the comparability of ALG-1001 to that of anti-vascular endothelial growth factor agents, the reasons for targeting integrins in...

  • Silicone deposits in repackaged anti-VEGF may cause permanent IOP spikes. Kahook, Malik Y. // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p15 

    The article focuses on the occurrence of intraocular pressure (IOP) spikes of patients that receive intravitreal injections, wherein it is said that IOP spikes is due to the silicone oil deposits that leach from the repackage vials of anti-vascular endothelial growth factor (VEGF) agents.

  • Evidence for anti-VEGF agent risk rates not significant at present. Cimberle, Michela // Ocular Surgery News;8/25/2013, Vol. 31 Issue 16, p22 

    The article reports on the presentation of Doctor Tien Y. Wong during a meeting of the European Society of Ophthalmology in Copenhagen on the need for additional clinical trials to determine the risk of side effects from using anti-vascular endothelial growth factor agents for the treatment of...

  • A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Arias, L.; Caminal, J.M.; Casas, L.; Masuet, C.; Badia, M.B.; Rubio, M.; Pujol, O.; Arruga, J. // British Journal of Ophthalmology;Dec2008, Vol. 92 Issue 12, p1636 

    Aims: The aim of this study was to compare two treatment options for choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD(: (1) bevacizumab administered once a month for 3 months and thereafter as needed (loading dose (LD)); and (2) bevacizumab administered as...

  • Ranibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration. Frampton, James // Drugs & Aging;2013, Vol. 30 Issue 5, p331 

    Ranibizumab (Lucentis), an inhibitor of all vascular endothelial growth factor (VEGF) A isoforms, is approved for the intravitreal treatment of neovascular age-related macular degeneration (AMD). In pivotal trials, monthly injections of ranibizumab were superior to verteporfin photodynamic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics